Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.

 

Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.

 

Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.

 

CHUL
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

223 entries « 1 of 23 »

Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D, HAUSER-RCT Investigators

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.

Journal Article

N Engl J Med, 2020, ISSN: 0028-4793.

Abstract | Links:

Gangloff A, Bergeron J, Lemieux I, Despres JP

Adiposity, lifestyle and vitamin D levels: the quest for answers.

Journal Article

Int J Obes (Lond), 44 (7), pp. 1628-1629, 2020, ISSN: 0307-0565.

| Links:

Gangloff A, Bergeron J, Lemieux I, Tremblay A, Poirier P, Almeras N, Despres JP

Relationships between circulating 25(OH) vitamin D, leptin levels and visceral adipose tissue volume: results from a 1-year lifestyle intervention program in men with visceral obesity.

Journal Article

Int J Obes (Lond), 44 (2), pp. 280-288, 2020, ISSN: 0307-0565.

Abstract | Links:

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Manvelian G, Pordy R

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.

Journal Article

J Clin Lipidol, 14 (1), pp. 88-97.e2, 2020, ISSN: 1933-2874.

Abstract | Links:

Muller-Wieland D, Rader DJ, Moriarty PM, Bergeron J, Langslet G, Ray KK, Manvelian G, Thompson D, Bujas-Bobanovic M, Roth EM

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.

Journal Article

J Clin Endocrinol Metab, 104 (11), pp. 5253-5262, 2019, ISSN: 0021-972X.

Abstract | Links:

Lemieux P, Weisnagel JS, Caron AZ, Julien AS, Morisset AS, Carreau AM, Poirier J, Tchernof A, Robitaille J, Bergeron J, Marette A, Vohl MC, Gagnon C

Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial.

Journal Article

Eur J Endocrinol, 181 (3), pp. 287-299, 2019, ISSN: 0804-4643.

Abstract | Links:

Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

Journal Article

N Engl J Med, 381 (6), pp. 531-542, 2019, ISSN: 0028-4793.

Abstract | Links:

Carter S, Lemieux I, Li Z, Almeras N, Tremblay A, Bergeron J, Poirier P, Despres JP, Picard F

Changes in IGFBP-2 levels following a one-year lifestyle modification program are independently related to improvements in plasma apo B and LDL apo B levels.

Journal Article

Atherosclerosis, 281 , pp. 89-97, 2019, ISSN: 0021-9150.

Abstract | Links:

Banerjee A, Alothman L, Couture P, Bergeron J, Belanger AM, Ruel I, Genest J

The Lifelong Burden of Homozygous Familial Hypercholesterolemia.

Journal Article

Can J Cardiol, 35 (10), pp. 1419.e1-1419.e4, 2019, ISSN: 0828-282X.

Abstract | Links:

Maltais A, Lemieux I, Almeras N, Tremblay A, Bergeron J, Poirier P, Despres JP

One-Year Lifestyle Intervention, Muscle Lipids, and Cardiometabolic Risk.

Journal Article

Med Sci Sports Exerc, 51 (10), pp. 2156-2165, 2019, ISSN: 0195-9131.

Abstract | Links:

223 entries « 1 of 23 »
Signaler des ajouts ou des modifications